期刊文献+

拉喹莫德的合成工艺研究 被引量:1

Synthesis of Laquinimod
原文传递
导出
摘要 目的合成拉喹莫德并对工艺进行研究。方法以2-氨基-6-氯苯甲酸为起始原料,经成环反应、甲基化反应、缩合反应、水解反应等合成了拉喹莫德。结果合成的拉喹莫德总收率为71.8%。结论工艺改进后,简化了操作过程,提高了拉喹莫德的收率。 Objective To synthesize Laquinimod and improve the synthetic technology. Methods Taking 2-amino-6- chlorobenzoic acid as the raw material, Laquinimod was obtained after a series of chemical reactions including cyclization, methylation, condensation, and hydrolization reaction. Results Laquinimod was prepared with an overall yield rate of 71.8%. Conclusion The improved procedure could simplify the synthesis and increase the yield of Laquinimod.
出处 《现代药物与临床》 CAS 2012年第1期11-13,共3页 Drugs & Clinic
关键词 拉喹莫德 2-氨基-6-氯苯甲酸 成环反应 甲基化反应 合成 Laquinimod 2-amino-6- chlorobenzoic acid cyclization reaction methylation reaction synthesis
  • 相关文献

参考文献4

  • 1曹伟,谢黎崖,孙洲亮.口服治疗多发性硬化药物——拉喹莫德[J].中国新药与临床杂志,2008,27(11):853-856. 被引量:3
  • 2Jonsson S, Andersson G; Svensson B, et al. Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship [J]. J Med Chem, 2004, 47: 2075-2008. 被引量:1
  • 3Spannmhlsvligen J K. Process for the manufacture of quinolinederivatives [P]. WO: 2003106424, 2002-06-12. 被引量:1
  • 4Wennerberg J, Bjork A, Fristed T, et al. Development of a practical and reliable synthesis of laquinimod [J]. Ovg Proc Res Dev, 2007, 11: 674-680. 被引量:1

二级参考文献14

  • 1李海峰.那他珠单抗治疗多发性硬化研究进展[J].中国新药与临床杂志,2005,24(11):906-909. 被引量:1
  • 2KIESEIER BC, WIENDL H. Oral disease-modifying treatments for multiple sclerosis: the story so far[J]. CNS Drugs, 2007, 21 (6) : 483-502. 被引量:1
  • 3WEISS L, BARAK V, ZEIRA M, et al. Cytokine production in Linomide-treated nod mice and the potential role of a Th (1)/Th (2) shift on autoimmune and anti-inflammatory processes [J]. Cytokine, 2002, 19(2): 85-93. 被引量:1
  • 4KARUSSIS D, ABRAMSKY O, ROSENTHAL Y, et al. Linomide downregulates autoimmunity through induction of Th2 cytokine production by lymphocytes[J]. Immunol Lett, 1999, 67 (3) : 203-208. 被引量:1
  • 5NOSEWORTHY JH, WOLINSKY JS, LUBIN FD, et al. Linomide in relapsing and secondary progressive MS: part Ⅰ trial design and clinical results[J]. Neurology, 2000, 54 (9) 1726-1733. 被引量:1
  • 6JONSSON S, ANDRSSON G, biological evaluation of new FEX T, et al. Synthesis and 1,2-dihydro-4-hydroxy-2-oxo-3-quinoline carboxamide for treatment of autoimmune disorders: structure-activity relationship[J]. J Med Chem, 2004, 47(8): 2075-2088. 被引量:1
  • 7BRUNMARK C, RUNSTROM A, OHLSSON L, et al. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis[J]. J Neuroinmmunol, 2002, 130 (1-2): 163-172. 被引量:1
  • 8YANG JS, XU LY, XIAO BG, et al. Laquinimod (ABR- 215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 eytokine TGF-beta in Lewis rats[J]. J Neuroimmunol, 2004, 156(1-2): 3-9. 被引量:1
  • 9RUNSTROM A, LEANDERSON T, OHLSSON L, et al. Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-beta k. o. and wild type mice[J]. J Neuroimmunol, 2006, 173(1-2): 69-78. 被引量:1
  • 10TUVESSON H, HALLIN I, PERSSON R, et al. Cytochrome P450 3A4 is the major enzyme responsible for the metabolism of laquinimod, a novel immunomodulator[J]. Drug Metab Dispos, 2005, 33(6): 866-872. 被引量:1

共引文献2

同被引文献11

  • 1Lichert,Frank.Oral Laquinimod reduces Relapse-Rates[J].Fortschritte der Neurologie Psychiatrie,2012,80(7):362. 被引量:1
  • 2Palma,Jose-Alberto.Oral Laqunimod for Multiple Sclerosis[J].New England Journal of Medicine,2012,366(26):2527. 被引量:1
  • 3GANT,Thomas,G.2-xox-1,2-dihydro-quinoline modulators of immune function:WO,2010028015[P].2008-09-03. 被引量:1
  • 4Dixit,Girish,Krishnadatt,et al.Highly pure Lquinimod of pharmaceutically acceptable sale thereof:WO,2010070449[P].2008-12-17. 被引量:1
  • 5Glick,Gary D.1,4-Benzodiazepine-2,5-diones and related compounds with therapeutic properties:WO,2011062765[P].2009-11-17. 被引量:1
  • 6Wennerberg J,Bj(o)rk A,Fristed T,et al.Development of a practical and reliable synthesis of laquinimod[J].Org Proc Res Dev,2007,11:674-680. 被引量:1
  • 7Tomassoli I,Ismaili L,Pudlo M,et al.Synthesis,biological,assessment and molecular modeling of new dihydroquinoline-3-carboxamides and dihydroquinoline-3-carbohydrazide derivatives as cholinesterase inhibitors,and Ca channel antagonists[J].European Journal of Medicinal Chemistry,2011,46:1-10. 被引量:1
  • 8J(o)nsson S,Andersson G,Svensson B,et al.Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders:structure-activity relationship[J].J Med Chem,2004,47:2075-2080. 被引量:1
  • 9Spannm(a)lsv(a)gen JK.Process for the manufacture of quinolinederivatives:WO,2003106424[P].2002-06-12. 被引量:1
  • 10曹伟,谢黎崖,孙洲亮.口服治疗多发性硬化药物——拉喹莫德[J].中国新药与临床杂志,2008,27(11):853-856. 被引量:3

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部